Condition
Kidney Transplant Candidates
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 2 (1)
Trial Status
Recruiting2
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06461546Phase 2WithdrawnPrimary
Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients
NCT06809075Not ApplicableRecruiting
Immunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation
NCT05489432Not ApplicableRecruiting
PREhabilitation of Candidates for REnal Transplantation
NCT01855438Not ApplicableCompletedPrimary
Increasing Communication About Live Donor Kidney Transplant
Showing all 4 trials